Skip to main content
Signal8
Launch Terminal
Jahr Robert Charles profile photo

Robert Charles Jahr

CIK: 0002076177

Transaction Breakdown

Open Market Buys (P)1 (33.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Outlook Therapeutics, Inc. logo
OTLK

Outlook Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • Outlook Therapeutics, Inc. logo
    OTLK

    Outlook Therapeutics, Inc.

    Aug 14, 2026
    Purchase(P)
    Direct
    151.5K shares-
  • Outlook Therapeutics, Inc. logo
    OTLK

    Outlook Therapeutics, Inc.

    Jul 21, 2026
    Award(A)

    Stock Option (Right to Buy)

    Direct
    100K shares-
  • Outlook Therapeutics, Inc. logo
    OTLK

    Outlook Therapeutics, Inc.

    Jul 1, 2025
    Award(A)

    Stock Option (Right to Buy)

    Direct
    800K shares-

1-3 of 3

About Jahr Robert Charles

Jahr Robert Charles (SEC CIK 0002076177) files insider reports with the SEC as Chief Executive Officer of Outlook Therapeutics, Inc. (OTLK).

Signal8 holds 4 ownership filings by Jahr Robert Charles (1 Form 3, 3 Form 4), filed between Jul 9, 2025 and Aug 14, 2026. Those filings report 3 transactions, from Jul 1, 2025 to Aug 14, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Jahr Robert Charles's filings is in ISELIN, NJ.

Recent filings by Jahr Robert Charles

  • Aug 14, 2026: Open-market purchase of OTLK shares (Form 4, code P).
  • Jul 21, 2026: Grant or award of OTLK derivative securities (Form 4, code A).
  • Jul 1, 2025: Grant or award of OTLK derivative securities (Form 4, code A).

Other insiders filing for Outlook Therapeutics, Inc. (OTLK)

How to read Form 4 transaction codes